Citicoline (CDP‐choline) add‐on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: A double‐blind, randomized placebo‐controlled trial

Objective We aimed to evaluate the efficacy and tolerability of citicoline add‐on therapy in treatment of negative symptoms in patients with stable schizophrenia. Methods In a double‐blind and placebo‐controlled study, patients with stable schizophrenia (DSM‐5) were randomized to receive either 2,50...

Full description

Saved in:
Bibliographic Details
Published in:Human psychopharmacology 2018-07, Vol.33 (4), p.e2662-n/a
Main Authors: Ghajar, Alireza, Gholamian, Faezeh, Tabatabei‐Motlagh, Maryam, Afarideh, Mohsen, Rezaei, Farzin, Ghazizadeh‐Hashemi, Maryam, Akhondzadeh, Shahin
Format: Article
Language:English
Subjects:
add‐on therapy
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Antipsychotics
CDP‐choline
Choline
Citicoline
Cytidine Diphosphate Choline - adverse effects
Cytidine Diphosphate Choline - therapeutic use
Double-Blind Method
Double-blind studies
Drug Therapy, Combination - adverse effects
Emotional behavior
Extrapyramidal system
Female
Humans
Male
Mental disorders
Middle Aged
Patients
primary negative symptoms
Psychiatric Status Rating Scales
Psychopathology
Randomization
Risperidone
Risperidone - therapeutic use
Schizophrenia
Schizophrenia - drug therapy
Schizophrenic Psychology
Treatment Outcome
α7 nAChR agonists
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective We aimed to evaluate the efficacy and tolerability of citicoline add‐on therapy in treatment of negative symptoms in patients with stable schizophrenia. Methods In a double‐blind and placebo‐controlled study, patients with stable schizophrenia (DSM‐5) were randomized to receive either 2,500 mg/day citicoline or placebo in addition to risperidone for 8 weeks. The patients were assessed using the positive and negative syndrome scale (PANSS), the extrapyramidal symptom rating scale (ESRS), and Hamilton depression rating scale (HDRS). The primary outcome was the difference in PANSS negative subscale score reduction from baseline to week 8 between the citicoline and the placebo groups. Results Sixty‐six individuals (out of 73 enrolled) completed the trial. The citicoline group demonstrated significantly greater improvement in negative scores, F(1.840, 118.360) = 8.383, p = .001, as well as general psychopathology, F(1.219, 78.012) = 6.636, p = .008; change in general psychopathology did not remain significant after adjustment, and total PANSS scores, F(1.633, 104.487) = 15.400, p 
ISSN:0885-6222
1099-1077
DOI:10.1002/hup.2662